Staff editor

Yvonne Nyavor – Improving analysis methods for Live Biotherapeutics Products

Yvonne Nyavor discusses the improvement of analysis methods for Live Biotherapeutics Products.

Proge Farm receives authorisation for the gynaecological drug containing its Lactobacillus plantarum p 17630 in the EU

Important goal reached by the Novara-based pharmaceuticals company, specialised in the production and marketing of live biotherapeutic products.

BiomeBank announces world first regulatory approval for donor derived microbiome drug

Formal approval of BiomeBank’s first-generation donor derived microbiome-based therapy product, BIOMICTRA registered in the Australian Register of Therapeutic Goods

Research Collaboration between Prof. Antonio Gasbarrini team at Gemelli Hospital and Asian Biotech companies, Coree and Dx&Vx

Healthy, diabetic, and obese people compared on diet and lifestyle using innovative technologies and multi-omics analysis

World-first microbiome-focused study may offer new hope to rheumatoid arthritis sufferers via improved gut health

Servatus are hopeful this study will eventuate into real benefits to sufferers of rheumatoid arthritis

OptiBiotix launches highly effective low dose prebiotic to stimulate targeted gut microbial growth

René Kamminga, CEO of OptiBiotix: “OptiXOS is unlike any prebiotic fibre commercially available in Europe today".

BioAro launches its genomics and microbiome services, bringing ease of access and the most comprehensive health analysis of DNA to the North American public before its global expansion

BioAro is a biotechnology company redefining healthcare through genetic sequencing, AI development and blockchain technologies.

Impact of Urbanization on Skin Microbiome

Chris Callewaert (Research Foundation Flanders - FWO) discussed the research he conducted on the effect of pollutants on skin microbiome and micobiome.

Clinical Microbiomics set to accelerate its expansion with EUR 10 million investment from Health for Life Capital™ II” managed by Seventure Partners

Funds to be invested to further advance Clinical Microbiomics’ leading microbiome profiling and systems biology platform, and to expand into new offerings and markets

The Strict Anaerobic Bacteria Fermentation Challenge: the Akkermansia case history

Marco Caspani, Chief Executive Officer at CSL Srl, discussed the challenges and the opportunity of producing anaerobic bacteria during the press conference on The Akkermansia Company.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Scroll to Top